{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:53:35Z","timestamp":1773842015508,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2172,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"AME","award":["K23 CA109613-A1"],"award-info":[{"award-number":["K23 CA109613-A1"]}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1093\/annonc\/mdt414","type":"journal-article","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T00:16:31Z","timestamp":1382400991000},"page":"3076-3081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M\/IVAC regimen for untreated Burkitt's lymphoma"],"prefix":"10.1016","volume":"24","author":[{"given":"A.M.","family":"Evens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.R.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kolesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Helenowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.F.","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt414_bb0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11864-002-0029-9","article-title":"Burkitt's and Burkitt-like lymphoma","volume":"3","author":"Evens","year":"2002","journal-title":"Curr Treat Options Oncol"},{"issue":"24","key":"10.1093\/annonc\/mdt414_bb0015","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1182\/blood-2012-12-475558","article-title":"Trends in survival of patients with Burkitt lymphoma\/leukemia in the USA: an analysis of 3691 cases","volume":"121","author":"Costa","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt414_bb0020","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt414_bb0025","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt414_bb0030","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt414_bb0035","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdt414_bb0040","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","article-title":"Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group","volume":"24","author":"Wasterlid","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt414_bb0045","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt414_bb0050","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s12185-010-0728-0","volume":"92","author":"Maruyama","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1093\/annonc\/mdt414_bb0055","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2141.2010.08447.x","article-title":"Rituximab in combination with CODOX-M\/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%","volume":"152","author":"Mohamedbhai","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt414_bb0060","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.1986.4.12.1732","article-title":"Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine","volume":"4","author":"Murphy","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt414_bb0065","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.1996.14.4.1252","article-title":"Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study","volume":"14","author":"Bowman","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt414_bb0070","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt414_bb0075","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2141.2011.08947.x","article-title":"RD-CODOX-M\/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and \u2018unclassifiable\u2019 highly aggressive B-cell lymphoma","volume":"156","author":"Corazzelli","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt414_bb0080","first-page":"685a","article-title":"Addition of Rituximab Improves Outcome of HIV Negative Patients with Burkitt Lymphoma Treated with the Lmba Protocol: Results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 Protocol. (IGR sponsored LMBA02, NCT00180882)","volume":"120","author":"Ribrag","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdt414_bb0085","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood."},{"key":"10.1093\/annonc\/mdt414_bb0090","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt414_bb0095","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","article-title":"Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response","volume":"97","author":"Jager","year":"2012","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdt414_bb0100","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bjh.12434","article-title":"Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma\/leukaemia: a Children's Oncology Group report","volume":"162","author":"Barth","year":"2013","journal-title":"Br J Haematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/12\/3076\/16702496\/mdt414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T01:05:55Z","timestamp":1679533555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419367481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0923753419367481"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt414","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M\/IVAC regimen for untreated Burkitt's lymphoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/annonc\/mdt414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}